Bristol Myers Squibb’s Opdivo Qvantig, the new subcutaneous version of its PD-1 inhibitor Opdivo (nivolumab), will be available starting in early January with a list price that is at parity with the original I.V. version of Opdivo, BMS chief commercialization officer Adam Lenkowsky told Scrip.
Key Takeaways
- The US FDA approved Bristol’s subcutaneous version of its PD-1 inhibitor Opdivo, which will be available in early January and priced at parity with the original I.V. formulation.
- BMS expects Opdivo Qvantig to take about 30%-40% of Opdivo’s business, protecting some of the blockbuster’s revenue after loss of exclusivity for the I.V. product in 2028
The FDA approved Opdivo Qvantig (nivolumab and hyaluronidase) on 27 December for all of the cancer indications included in the Opdivo label when the anti-PD-1 antibody is not combined with Bristol’s CTLA-4 inhibitor Yervoy (ipilimumab),
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
